Biocon signs 10-year Brazil supply deal for Pertuzumab breast cancer drug
Cite this
Citations are auto-generated; verify before publishing. The analysis classification is PolicyDhara's, not the source's.
Research or analytical publication — an evidence-based assessment informing policy design and evaluation. Shapes the intellectual framework within which policy debates occur.
Summary
Biocon has secured a 10-year supply contract for Pertuzumab in Brazil, gaining access to the country’s public healthcare market through a partnership with Bahiafarma and Bionovis.